27 results
10-K
2022 FY
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
-borne pathogens and the handling of biohazardous materials and chemicals. Although we maintain workers’ compensation insurance to cover the costs
10-K
2022 FY
EX-14.1
SCNI
Scinai Immunotherapeutics Ltd
17 Apr 23
Annual report
4:06pm
and with Company policies and procedures? (ii) Would you or the Company be compromised or embarrassed if the situation were known by your co-workers or the public
424B5
SCNI
Scinai Immunotherapeutics Ltd
28 Dec 21
Prospectus supplement for primary offering
5:20pm
laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials and chemicals. Although we maintain workers’ compensation
424B5
lhgzxyt5l g3qcw
27 Dec 21
Prospectus supplement for primary offering
6:22am
424B5
ifuub0gje
1 Feb 21
Prospectus supplement for primary offering
5:08pm
424B5
kuwd ebaglmtvca
29 Jan 21
Prospectus supplement for primary offering
12:00am
424B5
ms4j7j
2 Oct 20
Prospectus supplement for primary offering
12:00am
6-K
EX-99.3
2x0hj5jraxeqgwcerjs4
2 Oct 20
Condensed Interim Financial Statements
12:00am
6-K
EX-99.1
3om28ai
1 Sep 20
Report of Foreign Private Issuer
7:18am
POS AM
3v8wq ipo9oq7dgxx0
7 Jan 20
Prospectus update (post-effective amendment)
10:51am
F-1/A
a3fy6jvmcdnwsavxhzit
7 Jun 19
Registration statement (foreign) (amended)
11:42am
F-1/A
liz2zf63dj
6 Jun 19
Registration statement (foreign) (amended)
12:00am
F-1/A
oqvtiz7t3j15diinv
30 May 19
Registration statement (foreign) (amended)
8:46am
F-1/A
rlf8sf4xff3awt3zn5
6 May 19
Registration statement (foreign) (amended)
10:03am